Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma

studies in a murine lung cancer model demonstrated potent suppression of primary, distant, and metastatic tumors. This study underscored the potential of nano-PROTACs to synergistically integrate protein-selective degradation, immunometabolic reprogramming, and photodynamic immunotherapy, offering a promising strategy for lung adenocarcinoma treatment.